PT 16
Latest Information Update: 23 Mar 2007
At a glance
- Originator Palatin Technologies
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Feb 2002 Preclinical development for Cancer in USA (Unknown route)